Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
Zacks: Analysts Expect InVitae Corp (NYSE:NVTA) Will Announce Quarterly Sales of $62.11 Million
07:28am, Saturday, 18'th Apr 2020
Wall Street brokerages expect InVitae Corp (NYSE:NVTA) to post sales of $62.11 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for InVitae’s e
Stoke Therapeutics (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages
10:24am, Friday, 17'th Apr 2020
Stoke Therapeutics (NASDAQ:STOK) has received an average recommendation of “Buy” from the ten analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a
Geode Capital Management LLC Has $18.93 Million Holdings in InVitae Corp (NYSE:NVTA)
12:06pm, Thursday, 16'th Apr 2020
Geode Capital Management LLC grew its holdings in InVitae Corp (NYSE:NVTA) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fun
Exchange Traded Concepts LLC Increases Holdings in InVitae Corp (NYSE:NVTA)
09:30am, Thursday, 16'th Apr 2020
Exchange Traded Concepts LLC grew its holdings in shares of InVitae Corp (NYSE:NVTA) by 60.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Co
Is Enerplus Corp (ERF) A Good Stock To Buy?
06:50pm, Wednesday, 15'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Is InVitae Corporation (NVTA) A Good Stock To Buy?
06:50pm, Wednesday, 15'th Apr 2020
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Axovant, Invitae partner to increase access to genetic testing AXGT;NVTA
12:34pm, Wednesday, 15'th Apr 2020
Axovant, Invitae partner to increase access to genetic testing AXGT NVTA
Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis
12:00pm, Wednesday, 15'th Apr 2020
Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical genetics company
Goldman Sachs Group Inc. Raises Holdings in Stoke Therapeutics (NASDAQ:STOK)
11:11am, Wednesday, 15'th Apr 2020
Goldman Sachs Group Inc. boosted its position in shares of Stoke Therapeutics (NASDAQ:STOK) by 47.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities
InVitae Corp (NYSE:NVTA) Insider Sells $12,800.00 in Stock
09:04am, Wednesday, 15'th Apr 2020
InVitae Corp (NYSE:NVTA) insider Katherine Stueland sold 1,000 shares of the business’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $12.80, for a tot
Invitae Gained as Much as 11.8% Today, but It Might Not Last
07:49pm, Tuesday, 14'th Apr 2020
Investors might want to be cautious until the medical genetics company issues first-quarter 2020 operating results.
Bank of America Corp DE Has $4.59 Million Position in InVitae Corp (NYSE:NVTA)
10:50am, Tuesday, 14'th Apr 2020
Bank of America Corp DE increased its position in shares of InVitae Corp (NYSE:NVTA) by 34.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchang
3 Top Small-Cap Stocks to Buy Right Now
10:21am, Tuesday, 14'th Apr 2020
These three investments demonstrate different ways to profit from a market recovery.
InVitae Corp (NYSE:NVTA) Stock Position Reduced by Bank of New York Mellon Corp
09:32am, Tuesday, 14'th Apr 2020
Bank of New York Mellon Corp lessened its position in shares of InVitae Corp (NYSE:NVTA) by 0.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities &
Global PARP Inhibitor Biomarkers Market to Surpass US$ 2,170.3 Million by 2027, Says CMI
03:08pm, Monday, 13'th Apr 2020
SEATTLE, April 13, 2020 -- According to Coherent Market Insights, the global PARP inhibitor biomarkers market is valued at US$ 374.9 million in 2019, and is projected to.
